Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

[Current debates on rectal cancer].

Lasser P.

Gastroenterol Clin Biol. 2002 May;26(5 Suppl):B78-85. Review. French. No abstract available.

2.

Lateral pelvic lymph node dissection or chemoradiotherapy: which is the procedure of choice to reduce local recurrence rate in lower rectal cancer?

Watanabe T, Matsuda K, Nozawa K, Kobunai T.

Ann Surg. 2008 Aug;248(2):342-3; author reply 343. doi: 10.1097/SLA.0b013e3181820d0d. No abstract available.

PMID:
18650647
3.

The current management of rectal cancer.

Ross HM, Mahmoud N, Fry RD.

Curr Probl Surg. 2005 Feb;42(2):72-131. Review. No abstract available.

PMID:
15735619
4.

Rectal cancer.

Zampino MG, Labianca R, Beretta GD, Magni E, Gatta G, Leonardi MC, Chiappa A, Biffi R, de Braud F, Wils J.

Crit Rev Oncol Hematol. 2009 May;70(2):160-82. doi: 10.1016/j.critrevonc.2008.10.010. Epub 2008 Dec 6.

PMID:
19059790
5.

Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center.

Deo S, Kumar S, Shukla NK, Kar M, Mohanti BK, Sharma A, Raina V, Rath GK.

Indian J Cancer. 2004 Jul-Sep;41(3):120-4.

6.
7.

A model is a model: a decision analysis for rectal cancer.

Tepper J, Morris D.

J Natl Cancer Inst. 2004 Feb 4;96(3):164-5. No abstract available.

PMID:
14759975
8.

Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.

Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, Mortensen NJ.

Dis Colon Rectum. 2004 Dec;47(12):2025-31.

PMID:
15657650
9.

Sphincter preservation therapy for rectal cancer.

Aitken C, Breen E, Mamon HJ.

Clin Adv Hematol Oncol. 2003 Dec;1(12):735-40. Review.

PMID:
16258478
10.

Rectal cancer.

Legoux JL, Lehur PA, Penna C, Calais G, Roseau G, Calan LD.

Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S43-2S51. Review. No abstract available.

11.

The correlation between tumour regression grade and lymph node status after chemoradiation in rectal cancer.

Berho M, Oviedo M, Stone E, Chen C, Nogueras J, Weiss E, Sands D, Wexner S.

Colorectal Dis. 2009 Mar;11(3):254-8. doi: 10.1111/j.1463-1318.2008.01597.x. Epub 2008 May 29.

PMID:
18513188
12.

Local excision of rectal tumors.

Sharma A, Hartley J, Monson JR.

Surg Oncol. 2003 Jul;12(1):51-61. Review.

PMID:
12689670
13.

Recurrence after total mesorectal excision.

Bokey EL, Chapuis PH, Dent OF.

Dis Colon Rectum. 2005 Jun;48(6):1323; author reply 1323. No abstract available.

PMID:
15906122
14.

Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.

Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, D'Amico R, Conte PF, Natalini G.

Dis Colon Rectum. 2005 Oct;48(10):1851-7.

PMID:
16132481
15.

Prognostic markers of local relapse in rectal cancer: are we any further forward?

Johnston PG.

J Clin Oncol. 2006 Sep 1;24(25):4049-50. No abstract available.

PMID:
16943520
16.

Multidisciplinary treatment of resectable rectal cancer.

Ayala DN, Russo SM, Blackstock AW.

Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):383-94. doi: 10.1586/egh.09.33. Review.

PMID:
19673625
17.

Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish rectal cancer registry.

Jörgren F, Johansson R, Damber L, Lindmark G.

Colorectal Dis. 2010 Oct;12(10):977-86. doi: 10.1111/j.1463-1318.2009.01930.x.

PMID:
19438885
18.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
19.

Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.

Asoglu O, Karanlik H, Muslumanoglu M, Igci A, Emek E, Ozmen V, Kecer M, Parlak M, Kapran Y.

Eur J Surg Oncol. 2007 Dec;33(10):1199-206. Epub 2007 Apr 2.

PMID:
17400423
20.

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB 3rd, Fuchs CS.

J Clin Oncol. 2004 Feb 15;22(4):648-57.

PMID:
14966087

Supplemental Content

Support Center